$LQDA

Adair Jason sold $562K of LQDA

Adair Jason (Chief Business Officer) sold 7,863 shares of Liquidia Corp (LQDA) at an average of $71.51 ($71.39–$71.52, $0.56M total) across 2 trades on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Adair Jason
Published Jul 15, 2026, 12:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 15, 2026, 12:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Neutral
high confidence
Mentioned
$LQDA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on insider selling activity (size, price range, and 10b5-1 status) but does not introduce new fundamentals like earnings, guidance, trial results, or regulatory actions.

02

Market read

Useful for monitoring insider behavior, but unlikely to drive a durable repricing without additional company-specific catalysts.

03

What to watch

Traders may over-weight insider selling; the key missing context is whether other insiders also sold/bought around the same window and whether the company has concurrent fundamental catalysts.

Relevance 4/10Novelty 3/10Timing: after-hours filing update on 2026-07-14 for a 2026-07-13 sale

Background

The article is a SEC Form 4 insider transaction disclosure for Liquidia Corp, reported by CBO Adair Jason.

Company-level read

Ticker impact

$LQDANeutralHigh confidence
Context

Liquidia Corp disclosed an insider open-market sale by CBO Adair Jason of 7,863 shares at about $71.51 on a 10b5-1 plan.

Expected impact

Likely limited near-term price impact; any reaction would be sentiment-driven rather than earnings or guidance-related.

Evidence & confidence

The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan and no accompanying operational or financial disclosure.

Market effects

No clear sector read-through because the disclosure is an individual insider sale without new company guidance or clinical/regulatory updates.

None.

None.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may not reflect new negative information and could be mechanically scheduled.

Key entities

  • Liquidia Corp

    Company whose insider transaction was reported on Form 4.

  • Adair Jason

    Chief Business Officer who sold shares in an open-market transaction under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Liquidia Jumps 6.3% After HC Wainwright & Co. Maintains Buy

Liquidia Corporation (LQDA) rose 6.3% to $36.27 after four firms raised price targets, with an average of $57. HC Wainwright & Co. maintained a Buy rating, lifting its target to $65. The upgrades reflect optimism about the company's prospects and pipeline potential, with a 29.0% average target increase. LQDA's market cap is $3.2B.

$LQDAMedAI 8/10

Morrisville’s Liquidia Settles All Litigation With United Therapeutics, Keeping YUTREPIA Available for PAH Patients

Liquidia Corporation settled all litigation with United Therapeutics, resolving six lawsuits. The agreement allows YUTREPIA, a treatment for pulmonary arterial hypertension, to remain available. Liquidia will pay $380.7 million across 2026 and 2027, funded by YUTREPIA sales and cash on hand. The company reported $222.7 million in YUTREPIA net sales for Q3 2026 and has $396.1 million in cash.

$LQDAMed

H.C. Wainwright raises Liquidia stock price target on settlement

H.C. Wainwright raised its price target for Liquidia Technologies (LQDA) to $65 from $58, maintaining a Buy rating. The stock has surged 21% over the past week following a settlement with United Therapeutics, resolving all pending lawsuits. The settlement removes litigation overhang and allows Liquidia to focus on its pipeline. Analysts have mixed outlooks on the company's future performance.